Kei Kishimoto

Company: Selecta Biosciences Inc.

Job title: Chief Scientific Officer

Bio:

 

Seminars:

Addressing High Dose Vector Toxicity 2:30 pm

Immunogenicity of AAV is complex, and mitigation strategies should account for innate, humoral and cellular immune responses Toxicity associated with high vector doses is often linked to immunogenicity Mitigation of high dose toxicity may require a multipronged approach, including engineering of more efficient capsids and transgene cassettes and enabling multiple lower doses of AAV rather…Read more

day: Day Two